NCT04768855: A Study of LY3540378 in Healthy Participants

Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3540378 in healthy participants following single and multiple doses (Parts A and B) and multiple doses in Japanese (Part C) and Chinese (Part D) healthy participants. Blood tests will be performed to check how much LY3540378 gets into the bloodstream and how long it takes the body to eliminate it. This is a 4-part study and may last up to 70, 113, 113 and 113 days for each participant in Parts A, B, C, and D respectively.

Timeline

Start: 2021-03-17
Primary completion: 2022-05-30
Completion: 2022-05-30

Publications

Tham LS, Heerspink HJL, Wang X, Verdino P, Saifan CG, Benson EA, Goldsmith P, Wang Z, Testani JM, Haupt A, Sam F, Cherney DZI. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial. Nephrol Dial Transplant. 2024 Dec 20;40(1):109-122. doi: 10.1093/ndt/gfae112.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Volenrelaxin	Protein / enzyme biologic	—	Intravenous

Indications

No indication recorded.